Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Bi...
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
In recent years, cancer treatment has witnessed a number of novel approaches aimed at improving the therapeutic effects of existing treatments. Despite substantial advances, standard therapies such as chemotherapy and radiation have frequently failed to achieve long-term remission or cure for a large number of cancer patients. As a result, researchers have focused on novel treatment approaches, one of which targets the immunological checkpoint protein LAG-3 (Lymphocyte Activation Gene-3). Several LAG-3 inhibitors are currently in clinical trials, and while only 1 is commercially available, the LAG-3 inhibitors market is expected to grow at an unprecedented rate in the coming years due to rising cancer cases worldwide and increased interest in this emerging drug class by pharmaceutical companies and researchers. Key Report Highlights: Global LAG-3 Inhibitors Market Opportunity: USD 3 Billion by 2029 Global & Regional Market Analysis Commercially Approved LAG-3 Inhibitors: 1
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China [Yahoo! Finance]Yahoo! Finance
- Incyte Co. (NASDAQ: INCY) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Incyte Announces Final Results of Tender Offer [Yahoo! Finance]Yahoo! Finance
- Incyte Announces Final Results of Tender OfferBusiness Wire
- Incyte Announces Preliminary Results of Tender Offer [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 4/30/24 - Miss
INCY
Sec Filings
- 6/14/24 - Form SC
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- INCY's page on the SEC website